Stryker shares tumble despite strong Q2 results and raised guidance
WARSAW, Ind. - Zimmer Biomet Holdings, Inc. (NYSE:ZBH), a prominent player in the medical technology sector with a market capitalization of $18.3 billion, has announced the appointment of Kevin Thornal as the Group President of Global Businesses and the Americas, effective from July 1, 2025. In his new role, Thornal will be responsible for leading the Americas commercial organization and spearheading business strategy and execution for the company’s global Knees, Hips, S.E.T., and Data, Technology, and Enabling Solutions units. According to InvestingPro analysis, the company maintains a strong financial health score of GOOD, with liquid assets exceeding short-term obligations.
Chairman-Elect, President, and CEO Ivan Tornos expressed confidence in Thornal’s ability to drive the company’s U.S. performance and commercial execution, citing his impressive track record in the medical technology industry. Thornal’s career spans over two decades, including leadership roles at Nevro Corp. and Hologic, Inc., where he significantly contributed to the company’s growth and global expansion, particularly during the COVID-19 pandemic.
Thornal’s previous experience also includes a substantial tenure at Stryker Corp., where he was instrumental in achieving sustained growth within the North American sales sector for Stryker’s Interventional Spine business. His return to the orthopedics field is marked by enthusiasm for advancing Zimmer Biomet’s mission to alleviate pain and improve the quality of life for patients globally.
Zimmer Biomet, with its extensive history of over 90 years, is known for its innovative products and integrated digital and robotic technologies aimed at enhancing patient care. With operations in more than 25 countries and product sales in over 100 countries, the company continues to uphold its legacy through a culture of evolution and innovation. The company has maintained dividend payments for 14 consecutive years and achieved a robust gross profit margin of 71.2% in the last twelve months. For deeper insights into Zimmer Biomet’s financial performance and growth potential, investors can access comprehensive analysis through InvestingPro, which offers additional ProTips and detailed metrics.
This news release also includes forward-looking statements regarding Zimmer Biomet’s future plans and product offerings, which are subject to risks, uncertainties, and changes in circumstances that could affect actual results. Currently trading near its 52-week low, InvestingPro analysis indicates the stock is undervalued based on its Fair Value assessment, with analysts predicting continued profitability this year. The company cautions readers not to place undue reliance on these statements, which speak only as of the date they are made.
The announcement is based on a press release statement from Zimmer Biomet Holdings, Inc.
In other recent news, Zimmer Biomet reported first-quarter sales of $1.91 billion, reflecting a 2.3% growth on a constant currency basis, which slightly exceeded Wall Street’s expectations by $14 million. The company achieved adjusted earnings per share (EPS) of $1.81, surpassing consensus estimates by 2.5%. Despite these results, analysts have expressed concerns about future performance, particularly regarding tariffs and sales reorganization. Bernstein SocGen lowered its price target for Zimmer Biomet to $100, while TD Cowen adjusted its target to $104 due to tariff uncertainties. UBS maintained a Sell rating with a $105 target, noting a downward adjustment in EPS guidance to a range of $7.90 to $8.10. Morgan Stanley set a new price target of $95, citing underperformance in the U.S. Knee business and potential tariff impacts. Stifel also reduced its price target to $115, highlighting tariff-related headwinds affecting EPS forecasts for 2026. These developments reflect a cautious outlook from analysts regarding Zimmer Biomet’s future amid ongoing market challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.